Literature DB >> 17534047

Role of mast cells and basophils in chronic rhinosinusitis.

Ruby Pawankar1, Kun Hee Lee, Manabu Nonaka, Ryuta Takizawa.   

Abstract

Mast cells and basophils contribute to induction and/or maintenance of eosinophilic inflammation by a variety of mechanisms, including IgE-dependent and IgE-independent processes. The latter include a variety of stimuli that have only recently been elucidated, including mechanisms triggered by bacteria, virus, fungi, complement, or autoantibodies. MCs, and basophils contribute to inflammation both directly through the release of inflammatory mediators, cytokines and growth factors and indirectly through the activation of structural cells. Accumulating evidence places MCs (and most probably basophils) in a position of importance in the pathogenesis of CRS, particularly in the pathogenesis and progression of NP (Fig. 1). Mechanisms other than conventional IgE-dependent activation of MCs are intriguing as potential mechanisms of eosinophilic inflammation in non-allergic CRS/NP. Although it is not possible using current pharmacologic approaches to completely isolate the effects of MCs or basophils in CRS and NP pathogenesis, it seems most likely that such approaches will eventually be available. It might be expected that one or both of these cells will be shown to play important roles, particularly considering their potential for activation by IgE and non-IgE mechanisms, their production of a broad array of inflammatory mediators, cytokines and growth factors, and their unique assortment of proteases.

Entities:  

Mesh:

Year:  2007        PMID: 17534047

Source DB:  PubMed          Journal:  Clin Allergy Immunol        ISSN: 1075-7910


  9 in total

1.  Human mast cells express leptin and leptin receptors.

Authors:  Jasmien Taildeman; Claudina A Pérez-Novo; Isabelle Rottiers; Liesbeth Ferdinande; Anouk Waeytens; Veerle De Colvenaer; Claus Bachert; Pieter Demetter; Wim Waelput; Katleen Braet; Claude A Cuvelier
Journal:  Histochem Cell Biol       Date:  2009-02-25       Impact factor: 4.304

2.  2-(4-{2-[(phenylthio)acetyl]carbonohydrazonoyl}phenoxy)acetamide as a new lead compound for management of allergic rhinitis.

Authors:  Hee-Yun Kim; Sun-Young Nam; Jae-Bum Jang; Youngjin Choi; In-Cheol Kang; Hyung-Min Kim; Hyun-Ja Jeong
Journal:  Inflamm Res       Date:  2016-08-11       Impact factor: 4.575

3.  Increased expression and role of thymic stromal lymphopoietin in nasal polyposis.

Authors:  Satoko Kimura; Ruby Pawankar; Sachiko Mori; Manabu Nonaka; Satoru Masuno; Toshiaki Yagi; Kimihiro Okubo
Journal:  Allergy Asthma Immunol Res       Date:  2011-02-17       Impact factor: 5.764

Review 4.  Hypersensitivity to Aspirin and other NSAIDs: Diagnostic Approach in Patients with Chronic Rhinosinusitis.

Authors:  Joanna Makowska; Anna Lewandowska-Polak; Marek L Kowalski
Journal:  Curr Allergy Asthma Rep       Date:  2015-08       Impact factor: 4.806

Review 5.  Pathophysiology of chronic rhinosinusitis, pharmaceutical therapy options.

Authors:  Claus Bachert; Gabriële Holtappels
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2015-12-22

Review 6.  The Role of Autophagy in Eosinophilic Airway Inflammation.

Authors:  Jinju Lee; Hun Sik Kim
Journal:  Immune Netw       Date:  2019-02-04       Impact factor: 6.303

7.  Ginsenoside F1 Attenuates Eosinophilic Inflammation in Chronic Rhinosinusitis by Promoting NK Cell Function.

Authors:  So Jeong Kim; Jinju Lee; Woo Sun Choi; Hyo Jeong Kim; Mi-Yeon Kim; Sun Chang Kim; Hun Sik Kim
Journal:  J Ginseng Res       Date:  2021-03-29       Impact factor: 6.060

8.  Sweet taste receptor agonists attenuate macrophage IL-1β expression and eosinophilic inflammation linked to autophagy deficiency in myeloid cells.

Authors:  Jinju Lee; So Jeong Kim; Go Eun Choi; Eunbi Yi; Hyo Jin Park; Woo Seon Choi; Yong Ju Jang; Hun Sik Kim
Journal:  Clin Transl Med       Date:  2022-08

9.  Intracellular vesicle acidification promotes maturation of infectious poliovirus particles.

Authors:  Alexsia L Richards; William T Jackson
Journal:  PLoS Pathog       Date:  2012-11-29       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.